Janus base nanoparticles for targeted mrna and gene editing in kidney

Overview

Janus base nanoparticles (JBNps) present a breakthrough in targeted drug delivery, specifically designed for the kidney. These rod-shaped nanoparticles are engineered to deliver therapeutic mRNA and gene editing tools to tubular cells in the kidney with minimal toxicity and immunogenicity. Unlike traditional spherical lipid nanoparticles, JBNps are significantly smaller with a width of ~20nm, enhancing their ability to penetrate the kidney's complex filtration barriers. This technology promises to revolutionize treatment strategies for kidney diseases by ensuring precise and safe delivery of therapeutic agents.

Technical specifications

JBNps are constructed from small-molecule units inspired by DNA bases, which self-assemble into nanotubes through hydrogen bonding and base stacking. These nanotubes bundle together, encapsulating drug cargos to form the rod-shaped particles. Key features include:

• Biodegradability: JBNps are designed for efficient breakdown post-delivery, minimizing long-term toxicity.
• Endosomal escape: Effective release of therapeutic agents into the target cells.
• Low liver accumulation: Targeted delivery reduces off-target effects and enhances efficacy.
• Scalable production: Employs continuous flow mixing and homogenization for larger-scale manufacturing.

Technology readiness level

Currently at TRL 5, JBNps have undergone validation in lab settings, demonstrating effective kidney targeting and reduced liver accumulation. Future steps include optimizing loading capacity, stability assessments, and scaling up production while maintaining bio-potency and safety. These efforts will further validate the platform's readiness for clinical applications.